Pulmatrix receives fast track designation for Pulmazole for the treatment of Asthma-ABPA

This article was originally published here

Pulmatrix is currently enrolling patients in its ongoing randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety, tolerability, pulmonary function and biomarker response of Pulmazole in subjects with

The post Pulmatrix receives fast track designation for Pulmazole for the treatment of Asthma-ABPA appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply